Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$139.02 USD

139.02
2,609,579

+10.04 (7.78%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $139.40 +0.38 (0.27%) 7:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Zacks Industry Outlook Highlights: Amgen, ANI and Illumina

Zacks Industry Outlook Highlights: Amgen, ANI and Illumina

    Biotech Stock Outlook: Short-Term Pricing Pain to Prevail

    Decline in sales of high-profile drugs, pipeline setbacks and competitive pressure are likely to adversely impact the overall performance of the biotech sector in the short term.

      Alkermes' Aristada Initio Approved by FDA for Schizophrenia

      FDA approves Alkermes' (ALKS) Aristada Initio (aripiprazole lauroxil) for the treatment of schizophrenia in adults.

        Roche's Breast Cancer Study Meets Co-Primary Endpoint

        Phase III IMpassion130 study shows that Roche???s (RHHBY) Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer.

          Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?

          Sector ETF report for ARKG

            AMGN or ILMN: Which Is the Better Value Stock Right Now?

            AMGN vs. ILMN: Which Stock Is the Better Value Option?

              Nabaparna Bhattacharya headshot

              Genomics Market Gains Momentum: 3 DNA Stocks in Focus

              Here we discuss about how Genomics creates opportunities in MedTech for investors who are keen on putting money in the healthcare space.

                Is Illumina (ILMN) Outperforming Other Medical Stocks This Year?

                Is Illumina, Inc. (ILMN) Outperforming Other Medical Stocks This Year?

                  Novo Nordisk (NVO) Announces Results in Diabetes Studies

                  Novo Nordisk (NVO) announces results from a number of studies being evaluated to treat diabetes.

                    Zacks.com featured highlights include: Illumina, Lululemon, Surmodics and ConocoPhillips

                    Zacks.com featured highlights include: Illumina, Lululemon, Surmodics and ConocoPhillips

                      Anika Reports Top Line Data from CINGAL Study, Shares Slump

                      Anika Therapeutics' (ANIK) shares declined 37%, after the company reported disappointing data from its phase III Cingal 16-02 study in treating patients with osteoarthritis (OA) in the knee.

                        Tirthankar Chakraborty headshot

                        4 of the Best Efficient Stocks to Buy for Superb Returns

                        We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns

                          Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs

                          Novo Nordisk (NVO) enters into a research collaboration and option agreement with Kallyope, Inc. to develop novel therapies for diabetes and obesity.

                            Alexion (ALXN) Submits Application for ALXN1210 with FDA

                            Alexion Pharmaceuticals, Inc. (ALXN) submits a Biologics License Application (BLA) to the FDA for approval of ALXN1210 to treat patients with paroxysmal nocturnal hemoglobinuria (PNH).

                              Walgreens Boots' Retail Pharmacy Strong Despite Several Woes

                              Walgreens Boots' (WBA) consistent sales rise in the Retail Pharmacy International business is encouraging. Moreover, the company steadily gains traction from a slew of strategic deals.

                                BSX or BAX: Which is a Better Pick for Your Portfolio Now?

                                After considering various parameters and fundamentals, we help you make a choice between Boston Scientific (BSX) and Baxter (BAX).

                                  Valeant Down as FDA Refuses to Approve Duobrii For Psoriasis

                                  Valeant (VRX) suffers a setback as the FDA issues a CRL for its plaque psoriasis lotion, Duobrii.

                                    QIAGEN (QGEN) Banks on Molecular Diagnostics, Global Growth

                                    QIAGEN's (QGEN) progress with the test menu expansion is impressive. Earlier in Q1, the company also secures the Japanese approval for QuantiFERON-TB Gold Plus as an in vitro diagnostic to detect TB.

                                      Hologic's New Panther Fusion System Gets Health Canada Nod

                                      Hologic's (HOLX) receipt of Health Canada approval for the new Panther Fusion system and Panther Fusion assays, for respiratory virus infections, is expected to boost the top line in the near term.

                                        Here's Why You Should Add Amedisys (AMED) to Your Portfolio

                                        Amedisys' (AMED) solid performance in the recently launched Personal Care segment buoys optimism. A favorable demographic trend and strategic acquisitions also bode well for the company.

                                          Medtronic's Expanded IN.PACT Admiral FDA Nod to Aid APV Arm

                                          Medtronic's (MDT) receipt of FDA approval for 200mm and 250mm lengths of the IN.PACT Admiral Drug-Coated Balloon (DCB) is expected to boost the top line.

                                            Ryan McQueeney headshot

                                            Anatomy of Success: Illumina (ILMN)

                                            If investors had followed our ranking system when it flagged innovative biotech company, they would have witnessed massive profits.

                                              Dr. Reddy's/Mylan Get FDA Nod for First Generic of Suboxone

                                              Dr. Reddy's (RDY) and Mylan announced that the FDA approved the first generic version of Suboxone (Buprenorphine and Naloxone Sublingual Film) under-the-tongue film for the treatment of opioid addiction.

                                                Flex Pharma Down on Workforce Reduction, Ends Phase II Study

                                                Flex Pharma (FLKS) announced that the company is ending the phase II studies for its pipeline candidate FLX-787 in two indications. The company also plans to lower its workforce by about 60%.

                                                  Roche's (RHHBY) Avastin Gets Label Expansion Approval by FDA

                                                  Roche (RHHBY) announced that the FDA has approved the label expansion for its oncology drug Avastin in combination with chemotherapy, for the treatment of women with advanced ovarian cancer following initial surgical resection.